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Clinical question: Is there any new knowledge about the pathogenesis and treatment of 
age-related macular degeneration (AMD)?
Results: We now understand better the biochemical and pathological pathways involved in 
the genesis of AMD. Treatment of exudative AMD is based on intravitreal injection of new 
antivascular endothelial growth factor drugs for which there does not yet exist a unique recognized 
strategy of administration. No therapies are actually available for atrophic AMD, despite some 
experimental new pharmacological approaches.
Implementation: strategy of administration, safety of intravitreal injection
Keywords: age-related macular degeneration, antivascular endothelial growth factor, choroidal 
neovascularization, drusen, geographic atrophy
Age-related macular degeneration 
Definition: Age-related macular degeneration (AMD) is a condition characterized, 
in the early stages, by slow development and progression, absence of symptoms over 
a number of years, and extensive retinal deposits called drusen, often associated with 
pigmentary abnormalities (early AMD). The advanced presentation of AMD also 
includes geographic atrophy and choroidal neovascularization. The patient complains 
of metamorphopsia, discromatopsia, vision loss, and central scotoma.
Incidence: AMD is the leading cause of blindness and visual disability in patients 
over the age of 55 years in developed countries. The prevalence of early AMD is 18% 
in the population aged 65  –74 years and 30% in the population older than 74 years. 
Approximately 10%–15% of patients with AMD have severe central vision loss. 
The prevalence of geographic atrophy (atrophic AMD) is 3.5% in subjects older 
than 75 years, and accounts for approximately half the prevalence of choroidal 
neovascularization (exudative or neovascular AMD). Atrophic AMD accounts for 
approximately 25% of cases with severe central vision loss. Exudative AMD accounts 
for approximately 75% of cases with severe central vision loss.
Search sources: PubMed, Cochrane Library, Association for Research in Vision and 
Ophthalmology meeting abstracts, ClinicalTrial.gov.
Methods: A search of the English language literature was carried out using the 
PubMed and Cochrane Library databases from January 2000 through to December 
2010. For the same period, we referred to ClinicalTrial.gov and also analyzed in detail 
abstracts (sessions related to AMD, genetics, and new drugs) from the Association for Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Research in Vision and Ophthalmology meetings, looking 
for relevant studies in this field. The following keywords 
were used in the search: “genetic factors,” “pathogen,” 
“retinal pigment epithelium,” “Bruch’s membrane,” “chor-
oid,” “drusen,” “immunol” (MESH), “anti-VEGF drugs,” 
“new antiangiogen” (MESH), “intravitreal,” “prn,” “verte-
porfin,” “geographic atrophy,” “vitamins,” “fluorophores,” 
“myocardial infarction,” “mortality,” “adverse events,” 
and “safe.” The reference sections of papers located in 
this way were then searched for other relevant studies.   
A few articles published before 2000 were included for 
The evidence
historical purposes, but the present review is based mainly 
on articles published in the past decade.
Outcomes: Improvement of knowledge about AMD 
pathology, efficacy of new therapies, and avoidance of 
complications.
Consumer summary: AMD is an aging process of the 
central retina that may compromise high-resolution percep-
tion of images. There are new findings about the onset and 
development of the disease. There is good evidence that new 
intravitreal injection therapies are effective and safe.
Is there any new information about 
how AMD arises and develops?
Systematic reviews: 4
Case-control studies: 2
Cohort study: 1
Case series: 1
Longitudinal prospective studies: 2
Preclinical studies: 3
The systematic reviews concluded that, with advanc-
ing age, changes occur in macular structure, such as in the 
retinal pigment epithelium and Bruch’s membrane, as well 
as in ocular blood flow.1,2 Genetics may also play a role in 
the pathogenesis of AMD. The complex retinal pigment 
epithelium/choroid in the old normal mouse becomes an 
immunologically active tissue, recruits leukocytes from the 
circulation, and activates the complement cascade. On this 
basis, extrapolating to the human retina, it is supposed that 
the existence of an error in regulation of immunological 
activity causes AMD in an elderly individual.3 Although 
the pathogenesis of the disease is unknown, oxidative stress 
might have a meaningful role. Treatment with antioxidant 
vitamins and zinc can reduce the risk of developing advanced 
AMD by about a quarter in patients at moderate risk.4
Rod outer segment phagocytotic activity in immortalized 
human retinal pigment epithelium/Bruch’s membrane is sig-
nificantly higher on younger than on older Bruch’s membrane. 
This effect can be mimicked by nonenzymatic nitration of 
the extracellular matrix in vitro. Such changes due to aging 
of the retinal pigment epithelium/Bruch’s membrane seem 
to have a role in the pathogenesis of AMD.5 Retrospective 
observational case series have shown a relative new feature of 
AMD, ie, reticular pseudodrusen, considered to be a potential 
risk factor for late age-related maculopathy. Spectral-domain 
optical coherence tomography (OCT) shows granular hyper-
reflective material located primarily between the retinal 
pigment epithelium and the inner and outer segments of 
the photoreceptors. This unexpected location suggests that 
potential pathophysiologic mechanisms on both sides of the 
retinal pigment epithelium need to be taken into account in 
theories related to the development of AMD.6–8
Family and twin studies have shown that susceptibility 
to AMD is genetically influenced. Genetic investigations 
have shown that complement factor H, a regulator of the 
alternative complement pathway, and LOC387715/ARMS2 
and HTRA1 genes, are the most consistent genetic risk 
factors for AMD. The Y402H coding variant (rs1061170 
according to the Single Nucleotide Polymorphism Database 
nomenclature) in the complement factor H gene on chromo-
some 1, area q31, has been extensively studied via genetic 
and molecular approaches which provide strong statistical 
evidence for a disease association and a plausible biological 
context supporting this variant as an attractive candidate for 
a causal polymorphism leading to the development of AMD. 
However, the compelling association between Y402H and 
AMD observed in European cohorts is not as relevant to the 
disease risk in populations of Asian ancestry. The tyrosine-
to-histidine polymorphism (rs1061170) at amino acid 402 of 
complement factor H may be a primary pathogenic variation 
increasing the risk of developing AMD. Single nucleotide 
polymorphisms in chromosome 10q26 are associated with the 
risk of having AMD in several populations. Because several 
10q26 single nucleotide polymorphisms are associated with 
disease risk, it has been difficult to determine if the T allele of 
rs10490924 located in the coding region of the LOC387715/
ARMS2 (age-related maculopathy susceptibility 2) gene, or 
the A allele of rs11200638 located in the promoter region of Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
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high-temperature requirement factor A1 (HTRA1) has a role 
in the pathogenesis of the disease. The HTRA1 gene encodes 
a heat shock serine protease which is expressed in the retina 
and can regulate transforming growth factor beta signaling. 
The LOC387715/ARMS2 encodes a mitochondrial outer 
membrane protein that is also expressed in the retina.9–12 
However, the identification of genetic factors has not resulted 
in therapeutic strategies to modify the disease so far, and 
additional genetic and environmental factors are yet to be 
discovered to influence the onset and the progression of 
AMD.13
Conclusions
Alterations in macular structure that occur with advancing 
age, retinal blood flow modification, activation of inflam-
mation pathways, and genetics can interact in the onset and 
development of AMD (Figure 1).
Are new therapies for AMD effective?
Systematic reviews: 5
Meta-analyses: 1
Randomized controlled trials: 19
Case series: 1
Longitudinal prospective studies: 4
Longitudinal retrospective study: 1
Preclinical studies: 2
Concerning neovascular AMD, systematic reviews 
conclude that the prognosis is improved by clinical use of 
antivascular endothelial growth factor (anti-VEGF) drugs 
that target all isotypes of VEGF and maintain vision in over 
90% and substantial improvement in 25%–40% of patients 
(Table 1).14,15
Clinical trials have established the efficacy of treating 
patients with choroidal neovascularization in AMD using 
antiangiogenic therapies in a regimented continuous dosing 
schedule. Other trials have investigated the use of these 
Genetic factors
Senescence of RPE
Drusen
Alterations of Bruck’s membrane
Changes in extracellular matrix
Oxidative stress
Environmental risk factors
•
Choriocapillary anatomopathological alterations
Choroidal fluidodynamic failure
•
•
•
•
•
•
•
•
AMD
Figure 1 Main factors that may interact in the onset and development of age-related 
macular degeneration.
agents on an as-needed dosing schedule. Monthly intravitreal 
injection of ranibizumab was demonstrated to be superior 
to placebo and also to photodynamic therapy in minimally 
classic and occult subtypes of neovascular AMD.16,17
Long-term regular follow-up is necessary for patients 
treated with ranibizumab to obtain and preserve any 
significant visual acuity gain, and not only to achieve visual 
stabilization.18 Ranibizumab given monthly for three months 
was superior to placebo for treatment of neovascular AMD.19 
However, visual gain and overall results were less favorable 
compared with monthly intravitreal injection of ranibizumab. 
There is evidence that after the first three monthly injections 
of ranibizumab, retreatment should be performed when 
typical signs of active lesion occur, such as deterioration of 
visual acuity and retinal thickening.20 It was clearly demon-
strated that quarterly maintenance dosing of ranibizumab 
was inferior to monthly dosing in the treatment of all types 
of neovascular AMD.21
An OCT-guided variable dosing regimen with intravitreal 
ranibizumab resulted in visual acuity outcomes compa-
rable with those of previous Phase III studies over 12 and 
24 months, but with fewer injections.22–24 Uncertainty remains 
regarding the relative benefits of pegaptanib compared with 
ranibizumab and other unlicensed drugs (eg, bevacizumab), 
due to the nature of the evidence. Head-to-head randomized 
controlled trials and economic evaluations comparing these 
alternatives are needed.24–26 Combination therapy is likely to 
play an increasing role in treating neovascular AMD, and may 
improve visual acuity outcomes, reduce retreatment rates, and 
consequently extend treatment-free intervals.27 Combination 
with photodynamic therapy seems to reduce the number of 
injections and to maintain the effects of treatment for longer.28 
This may lead to a lower treatment burden for many patients 
and potentially to a reduction of overall treatment costs. 
Numerous new drugs under investigation suggest that new 
combinations will follow.
New antiangiogenic approaches acting in various steps 
of the angiogenic cascade are being studied and may soon 
be available.29 Randomized controlled clinical trials are 
necessary to support the use of these molecules, the production 
of which is growing. Among the factors involved in angio-
genesis, the most attention has been given to VEGF. Many 
modalities other than VEGF blockers are under investigation 
for their potential to inhibit VEGF, including VEGF Trap-Eye 
(Regeneron Pharmaceuticals Inc, Tarrytown, NY) and small 
interfering RNA therapies. Other investigational strategies 
have focused on blocking the downstream effects of VEGF 
and targeting other factors involved in angiogenesis. VEGF Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Trap-Eye is a recombinant protein consisting of the binding 
regions of VEGF receptors 1 and 2 and the constant region of 
human immunoglobulin, G1. The binding of VEGF Trap-Eye 
to VEGF forms an inert stable complex, thereby blocking 
proangiogenic effects.30
RNA interference has a catalytic mechanism that enables 
one small interfering RNA (siRNA) molecule to facilitate the 
cleavage of thousands of mRNA molecules. Two siRNAs are 
under investigation as potential treatments for neovascular 
AMD, one targeting VEGF-A (bevasiranib, OPKO Health, 
Miami, FL)31 and the other targeting the VEGF receptor 1 
(AGN211745 or SIRNA-027, Allergan, Irvine, CA).32 VEGF 
binds to two receptor tyrosine kinases, ie. VEGF R1 and 
VEGF R2. Several tyrosine kinase inhibitors may provide a 
means to target these receptors, including vatalanib (previ-
ously known as PTK787, Novartis AG, Basel, Switzerland).33 
Vatalanib blocks the phosphorylation of VEGF and platelet-
derived growth factor receptors, and has been shown to pre-
vent retinal neovascularization induced by ischemia in mice. 
Vatalanib is currently under investigation in clinical trials for 
patients with choroidal neovascularization due to AMD.
Multikinase inhibitors, such as TG100572 (TargeGen, 
San Diego, CA), are also under investigation for neovascular 
AMD.34 Delivery of TG100572 to the retina and choroid 
seems to be enhanced by administration in the form of a 
prodrug, TG100801. Topical use of TG100801 (TargeGen)35 
suppressed laser-induced choroidal neovascularization in 
mice and reduces fluorescein leakage and retinal thickening 
in a rat model of retinal vein occlusion. Other multikinase 
inhibitors under investigation include pazopanib (GW786034, 
GlaxoSmithKline, Philadelphia, PA),36 which inhibits VEGF 
receptors 1, 2, and 3, platelet-derived growth factor receptors 
α and β, and c-kit. Neovascular AMD is more than simply a 
vascular disease, and includes not only angiogenic but also 
vascular and inflammatory components. The important role 
of complement in the pathogenesis of neovascular AMD 
has raised interesting possibilities for the development of 
new treatments. A number of agents are under investiga-
tion as potential complement inhibitors, including TA106 
(a monoclonal antibody against complement 3, Taligen 
Therapeutics, Aurora, CO), POT-4 (a peptide that binds to 
complement 3, Potential Pharmaceuticals, Louisville, KY),37 
and ARC1905 (an anticomplement 5 aptamer, Ophthotech, 
Princeton, NJ).38
There is also evidence for the involvement of a 
wide variety of inflammatory cells in neovascular AMD 
pathogenesis. Targeting leucocytes or adhesion molecules 
involved in their recruitment may provide the potential 
for new treatments. For example, blockade of vascular 
adhesion protein-1, an endothelial cell adhesion molecule 
involved in leucocyte recruitment, has been shown to reduce 
choroidal neovascularization size, fluorescein leakage, and 
macrophage accumulation, while reducing the expression of 
inflammatory mediators, such as tumor necrosis factor-α, 
monocyte chemoattractant protein-1, and intercellular 
adhesion molecule-1.
Platelet-derived growth factor may also play a role in 
choroidal neovascularization, and acts as a mitogen for pericytes, 
smooth muscle cells, fibroblasts, and other mesenchymal cells. 
Pericytes may be critical for the maintenance of established 
blood vessels, and may be important in the maturation 
process in choroidal neovascularization. There is evidence 
that, in newly formed vessels, there is a period during which 
endothelial cells depend on VEGF and are responsive to the 
withdrawal of platelet-derived growth factor. In contrast, estab-
lished mature vessels may exhibit less dependence on VEGF 
and may be associated with resistance to anti-VEGF, or with 
rapid recurrence of choroidal neovascularization due to AMD. 
These observations are consistent with evidence that blockade 
of both VEGF-A and platelet-derived growth factor is more 
effective at suppressing neovascularization in experimental 
models than blockade of VEGF-A alone. Platelet-derived 
growth factor has been shown to stimulate angiogenesis 
and pericyte recruitment. The loss of pericytes from retinal 
vessels may be associated with vascular abnormalities and 
instability, including the formation of microaneurysms and 
vascular permeability. Blocking platelet-derived growth factor 
appears to result in loss of pericytes and possible regression 
of maturing neovascularization. Continued production of 
VEGF-A by pericytes under certain conditions may protect 
endothelial cells from the effects of VEGF-A blockade by anti-
VEGF agents. Anti-platelet-derived growth factor, Aptamer 
E10030 (Ophthotech), targets platelet-derived growth factor 
which regulates neovascular pericytes.39 In preclinical models, 
E10030 successfully induced neovascular regression when 
administered in combination with anti-VEGF agents. This 
effect is further supported by published studies in which 
inhibition of binding of platelet-derived growth factor to its 
receptor, PDGFR-β, plus an anti-VEGF agent, causes neo-
vascular regression in ocular angiogenesis models. A Phase II 
study of E10030 in combination with ranibizumab is assess-
ing the efficacy and safety of this combination treatment 
regimen.
Integrins are cell adhesion molecules involved in 
the mediation of cell-cell, cell-extracellular matrix, and 
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a heterodimer with a 1α and a 1β subunit. There is growing 
evidence that β1 integrins are involved in angiogenesis, 
especially with regard to the maturation and organization of 
neovascularization. Blockade of integrins has been shown to 
inhibit endothelial cell proliferation and induce apoptosis, 
while several inhibitors of angiogenesis, such as endostatin, 
can mediate their effects by binding to integrins. Integrins 
have also been shown to play a role in VEGF-mediated 
cell adhesion and endothelial cell migration, which can be 
suppressed by blocking integrin α5β1 with antibodies. There 
has been interest in the role of integrins in neovascular AMD, 
based on evidence that integrin receptors play important 
roles in tumor angiogenesis. Blockade of integrin α5β1, the 
most important of the fibronectin receptors, has been shown 
to result in suppression of tube formation stimulated by 
VEGF and in apoptosis of proliferating endothelial cells. An 
anti-α5β1 antibody inhibited VEGF-dependent and VEGF-
independent angiogenesis in an experimental model, while 
anti-VEGF inhibited only VEGF-dependent angiogenesis. 
Volociximab (M200, Ophthotech), a chimeric monoclonal 
antibody targeting integrin α5β1 to block its ligation of 
fibronectin, has robustly inhibited human umbilical vein 
endothelial cell tube formation in laboratory tests. It does 
so regardless of initial growth factor stimulation. It has also 
inhibited neovascularization in primate choroid tissue and 
tumor angiogenesis in rabbits.40
Pigment epithelium-derived factor is an antiangiogenic factor 
that counters the effects of VEGF. Therefore, administering 
pigment epithelium-derived factor could have potential 
antiangiogenic effects, although high doses appear to have the 
opposite effect and lead to increased neovascularization. It may 
also be possible to increase local production of this factor by 
delivering the pigment epithelium-derived factor gene to the 
retina using an adenovector.
Evidence is gathering concerning the role of an activated 
immune system in AMD. Accordingly, overexpression of 
the pleiotropic cytokine, tumor necrosis factor, which is 
mainly produced by T cells and monocytes, has been found 
in neovascular membranes of eyes with AMD. Interactions 
between tumor necrosis factor and its receptor(s) are important 
for the regulation of the activities of the retinal pigment epi-
thelium, including cell attachment, spreading, chemotaxis, 
migration, and proliferation. Expression of various apoptotic 
factors in retinal pigment epithelium cells in diseases such 
as AMD is upregulated by tumor necrosis factor. A drug that 
interferes with tumor necrosis factor/tumor necrosis factor 
receptor interactions may represent a legitimate therapeutic 
approach for patients with neovascular AMD.41
A variety of other potential antiangiogenic treatments 
could merit further investigation in neovascular AMD, includ-
ing microtubule inhibitors, nucleic acid therapies, peroxi-
some proliferator-activated receptor agonists, and rapamycin. 
Further investigation is needed to determine whether these 
agents have the potential to target angiogenesis and improve 
outcomes in neovascular AMD.
Systematic reviews suggest that, unlike neovascular 
AMD, there is no treatment for geographic atrophy presently 
approved by health authorities.
In one study, people at high risk of developing advanced 
AMD lowered their risk by about 25% when treated with a 
high-dose combination of vitamin C, vitamin E, beta-carotene, 
and zinc. In the same high-risk group, these nutrients reduced 
the risk of vision loss caused by advanced AMD by about 
19%. For those study participants who had either no AMD 
or early AMD, the nutrients did not provide an apparent 
benefit.42 Observational studies have also suggested benefits 
from increased dietary intake of macular xanthophylls and 
omega-3 fatty acids.43
Fenretinide, a hydrophobic drug structurally derived from 
vitamin A, reduces lipofuscin deposition interfering with 
vitamin A transport proteins, known as fluorophores, that 
seem to contribute directly to the pathogenesis of AMD.44 
Fenretinide has shown positive results for slowing the 
progression of dry macular degeneration.45
Many publications have linked both oxidative stress 
and inflammation to the progression of geographic atrophy. 
OT-551 is a topically-dosed, patented small molecule that 
acts on oxidative stress and disease-induced inflammation.46 
Topical OT-551 has been demonstrated to be well tolerated by 
patients with geographic atrophy and not associated with any 
serious adverse effects. However, the absence of significant 
effects on other outcomes suggests that OT-551, with the 
current concentration and mode of delivery, may have limited 
or no benefit as a treatment for geographic atrophy.47
Conclusions
There are still many unanswered questions to be resolved by 
future research. Regarding exudative AMD treatment, what 
regimen of anti-VEGF administration is better, ie. monthly 
dosing or OCT-guided dosing? How many patients need 
retreatment, and how many injections are needed during the 
second and third year? Do any situations alter the pharma-
cogenetics of anti-VEGF drugs (eg, vitrectomy surgery or 
glaucoma medications)?
Quarterly injections of ranibizumab seems to result in 
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An OCT-guided regimen appeared to achieve visual results 
similar to those from monthly dosing, with fewer injections, 
but patients still require monthly visits, examinations, and 
OCT assessment. As regards geographic atrophy, it may be 
possible to reduce the progression of dry AMD with a multi-
vitamin integration, and many molecules are being tested.
Are new therapies for AMD safe?
Systematic review: 1
Randomized controlled trials: 2
Case series: 1
Longitudinal retrospective study: 1
Recent retrospective cohort studies have included 
patients receiving photodynamic therapy, intravitreal 
pegaptanib, bevacizumab, or ranibizumab. The mortality 
risk was significantly lower with ranibizumab therapy than 
with photodynamic therapy or pegaptanib use, and the 
risk of myocardial infarction was significantly lower with 
ranibizumab than with photodynamic therapy. There were no 
significant differences in the mortality or myocardial infarction 
risk between bevacizumab use and the other therapies. No 
significant relationship was found between treatment group 
and bleeding events or stroke.48
A review of the current literature suggests that anti-VEGF 
is generally a safe and effective treatment for neovascular 
AMD for up to 2–3 years. Presently, there is Level 1 evi-
dence to substantiate this conclusion for pegaptanib and 
ranibizumab, but not for bevacizumab.49 Multiple intravitreal 
ranibizumab injections are safe over the long term for treating 
choroidal neovascularization in AMD. Ranibizumab is well 
tolerated, and the incidence of serious adverse events is low 
and unrelated to dose.50,51 Regarding local complications, 
intravitreal injection may generate subconjunctival hemor-
rhage, followed by a transient increase in intraocular pressure, 
tractional retinal detachments, bacterial endophthalmitis, and 
uveitis. More rarely observed are rhegmatogenous detach-
ment and vitreous hemorrhage.52
Conclusions
There is no significant clinical evidence that use of anti-
VEGF drugs is associated with systemic adverse events. 
Some ocular complications may occur.
The practice
Potential pitfalls
While monthly injections of intravitreal anti-VEGF therapy 
for neovascular AMD have produced visual outcomes 
superior to prior therapies, the frequency of office visits and 
injections can place a tremendous burden on patients and 
the health care system. Unfortunately, large and potentially 
devastating submacular hemorrhages may occur almost 
immediately after a high-quality OCT examination showing 
an absence of fluid. Theoretically, eyes treated with an OCT-
guided “as needed” regimen, in which patients may go for 
long intervals without VEGF suppression, could be at greater 
risk for sight-threatening submacular hemorrhages compared 
with eyes receiving more frequent and regular anti-VEGF 
treatments. There are no approved treatments for geographic 
atrophy.
Management
Even if anti-VEGF agents become cheaper and more available, 
an increasing number of patients will have to rely on them 
and, as a result, the burden on the health care system will 
increase. It may be more cost-effective for AMD prevention 
to perform:
•	 Automonitoring
•	 Periodic eye examination
•	 Angiography with fluorescein and indocyanine green, 
OCT
In case of neovascular AMD, it is important to follow 
the patient with strict controls in order to detect recurrences 
as soon as possible using:
•	 Patient information (increasing of visual distortion)
•	 Worsening of visual acuity
•	 Ophthalmoscopic appearance of macular hemorrhages
•	 OCT features
Treatment
For prevention of AMD:
•	 Use nutritional supplements, such as the Age Related Eye 
Disease Study formula, lutein and zeaxanthin, omega-3 
fatty acid, and berry extracts
•	 Modify lifestyle, including cessation of smoking and 
reduction of body mass index
•	 Filter sunlight, ie, with sunglasses and blue-blocking 
intraocular lenses
For geographic atrophy:Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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•	 No treatment is commercially available at present
For choroidal neovascularization:
•	 Intravitreal injections of anti-VEGF drugs
Indications for specialist referral:
•	 A familial history of AMD
•	 Progressive or sudden worsening of visual acuity
•	 Occurrence of visual distortion or visual perception of 
central dark spot
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